The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a ...
Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis ...
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Nonlinear dendritic integration in single presubicular neurons provides a mechanism for combining vestibular-based head-direction signals and visual landmark signals to anchor the brain’s internal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback